Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter ended September 30, 2014 under International Financial Reporting Standards (IFRS).
Key Highlights (Q2 FY15)
•Consolidated revenues at Rs. 35.9 billion, year-on-year growth of 7%.
?Revenues from the Global Generics (GG) segment at Rs. 28.9 billion, YoY growth of 9%
Help employers find you! Check out all the jobs and post your resume.
